1. Ability to file for accelerated approval -- the most important de-risking event.
2. Immunoblot data to quantify (and confirm) increased dystrophin production in eteplirsen patients.
3. Questionable data for PRO051, the competing DMD drug from GlaxoSmithKline ( GSK) and Prosensa. The biggest concern with PRO051 is kidney toxicity at higher doses. Data from a 53-patient, phase II study are expected in the first quarter 2013, while data from the 180-patient pivotal phase III study are expected at the end of 2013.
4. Sarepta raising money or signing a partner. Tanner believes the former is preferred over the latter. Sarepta shares closed Tuesday at $33.33. The stock is down 26% from its $45 per share high reached last week following the release of the eteplirsen data. Still, Sarepta shares are up 640% this year. -- Reported by Adam Feuerstein in Boston. Follow @AdamFeuerstein